Bone protection in breast cancer: durability and discontinuation
Authors:
- 20 April 2026
- journal article
- letter
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (4) , 1003-1004
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysisOsteoporosis International, 2026
- Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patientsESMO Open, 2025
- Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled TrialJournal of Clinical Oncology, 2024
- Long-Term Outcomes of Adjuvant Denosumab in Breast CancerNEJM Evidence, 2022
- Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTSThe Journal of Clinical Endocrinology & Metabolism, 2020